157 related articles for article (PubMed ID: 34856892)
1. Recent Trends in Tubulin-Binding Combretastatin A-4 Analogs for Anticancer Drug Development.
Paidakula S; Nerella S; Kankala S; Kankala RK
Curr Med Chem; 2022; 29(21):3748-3773. PubMed ID: 34856892
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies.
Sharma S; Gupta MK; Saxena AK; Bedi PM
Anticancer Agents Med Chem; 2017; 17(2):230-240. PubMed ID: 27141882
[TBL] [Abstract][Full Text] [Related]
3. Developments of combretastatin A-4 derivatives as anticancer agents.
Shan Y; Zhang J; Liu Z; Wang M; Dong Y
Curr Med Chem; 2011; 18(4):523-38. PubMed ID: 21143124
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of silicon-containing tubulin polymerization inhibitors: replacement of the ethylene moiety of combretastatin A-4 with a silicon linker.
Nakamura M; Kajita D; Matsumoto Y; Hashimoto Y
Bioorg Med Chem; 2013 Dec; 21(23):7381-91. PubMed ID: 24139940
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Combretastatin A-4 Inspired Inhibitors of Tubulin Polymerization: An Update.
Baytas SN
Curr Med Chem; 2022; 29(20):3557-3585. PubMed ID: 34986762
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, antiproliferative, anti-tubulin activity, and docking study of new 1,2,4-triazoles as potential combretastatin analogues.
Mustafa M; Abdelhamid D; Abdelhafez EMN; Ibrahim MAA; Gamal-Eldeen AM; Aly OM
Eur J Med Chem; 2017 Dec; 141():293-305. PubMed ID: 29031074
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A-4 analogues as antimitotic antitumor agents.
Nam NH
Curr Med Chem; 2003 Sep; 10(17):1697-722. PubMed ID: 12871118
[TBL] [Abstract][Full Text] [Related]
8. Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models.
Reipsch F; Biersack B; Lucas H; Schobert R; Mueller T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884888
[TBL] [Abstract][Full Text] [Related]
9. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.
Lin CM; Singh SB; Chu PS; Dempcy RO; Schmidt JM; Pettit GR; Hamel E
Mol Pharmacol; 1988 Aug; 34(2):200-8. PubMed ID: 3412321
[TBL] [Abstract][Full Text] [Related]
10. Discovery, synthesis, activities, structure-activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review.
Singh SB
Nat Prod Rep; 2024 Feb; 41(2):298-322. PubMed ID: 38009216
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
[TBL] [Abstract][Full Text] [Related]
13. Combretastatin-based compounds with therapeutic characteristics: a patent review.
Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
[No Abstract] [Full Text] [Related]
14. Synthesis and biological evaluation of cis-restricted triazole/tetrazole mimics of combretastatin-benzothiazole hybrids as tubulin polymerization inhibitors and apoptosis inducers.
Subba Rao AV; Swapna K; Shaik SP; Lakshma Nayak V; Srinivasa Reddy T; Sunkari S; Shaik TB; Bagul C; Kamal A
Bioorg Med Chem; 2017 Feb; 25(3):977-999. PubMed ID: 28034647
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents.
Stefański T; Mikstacka R; Kurczab R; Dutkiewicz Z; Kucińska M; Murias M; Zielińska-Przyjemska M; Cichocki M; Teubert A; Kaczmarek M; Hogendorf A; Sobiak S
Eur J Med Chem; 2018 Jan; 144():797-816. PubMed ID: 29291446
[TBL] [Abstract][Full Text] [Related]
16. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
Ducki S; Rennison D; Woo M; Kendall A; Chabert JF; McGown AT; Lawrence NJ
Bioorg Med Chem; 2009 Nov; 17(22):7698-710. PubMed ID: 19837593
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy.
Sriram M; Hall JJ; Grohmann NC; Strecker TE; Wootton T; Franken A; Trawick ML; Pinney KG
Bioorg Med Chem; 2008 Sep; 16(17):8161-71. PubMed ID: 18722127
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors.
Romagnoli R; Oliva P; Salvador MK; Camacho ME; Padroni C; Brancale A; Ferla S; Hamel E; Ronca R; Grillo E; Bortolozzi R; Rruga F; Mariotto E; Viola G
Eur J Med Chem; 2019 Nov; 181():111577. PubMed ID: 31400707
[TBL] [Abstract][Full Text] [Related]
20. E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes.
Pettit RK; Pettit GR; Hamel E; Hogan F; Moser BR; Wolf S; Pon S; Chapuis JC; Schmidt JM
Bioorg Med Chem; 2009 Sep; 17(18):6606-12. PubMed ID: 19709889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
